| Laboratory findings in COVID-19 diagnosis and prognosis A Pourbagheri-Sigaroodi, D Bashash, F Fateh, H Abolghasemi Clinica chimica acta 510, 475-482, 2020 | 338 | 2020 |
| The PI3K/Akt signaling axis in Alzheimer’s disease: a valuable target to stimulate or suppress? E Razani, A Pourbagheri-Sigaroodi, A Safaroghli-Azar, A Zoghi, ... Cell Stress and Chaperones 26 (6), 871-887, 2021 | 152 | 2021 |
| The PI3K/Akt/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles MJ Sanaei, S Razi, A Pourbagheri-Sigaroodi, D Bashash Translational Oncology 18, 101364, 2022 | 127 | 2022 |
| The role of toll‐like receptor 4 (TLR4) in cancer progression: A possible therapeutic target? B Kashani, Z Zandi, A Pourbagheri‐Sigaroodi, D Bashash, SH Ghaffari Journal of cellular physiology 236 (6), 4121-4137, 2021 | 84 | 2021 |
| Toll‐like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists A Keshavarz, A Pourbagheri‐Sigaroodi, P Zafari, N Bagheri, SH Ghaffari, ... IUBMB life 73 (1), 10-25, 2021 | 70 | 2021 |
| Toll‐like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis Y Mokhtari, A Pourbagheri‐Sigaroodi, P Zafari, N Bagheri, SH Ghaffari, ... Journal of Cellular and Molecular Medicine 25 (2), 639-651, 2021 | 69 | 2021 |
| The PI3K/Akt/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions ABS Khorasani, A Pourbagheri-Sigaroodi, A Pirsalehi, A Safaroghli-Azar, ... European Journal of Pharmacology 898, 173983, 2021 | 58 | 2021 |
| COVID‐19‐related coagulopathy: A review of pathophysiology and pharmaceutical management M Kohansal Vajari, M Shirin, A Pourbagheri‐Sigaroodi, ME Akbari, ... Cell biology international 45 (9), 1832-1850, 2021 | 56 | 2021 |
| The contributory role of lymphocyte subsets, pathophysiology of lymphopenia and its implication as prognostic and therapeutic opportunity in COVID-19 M Delshad, N Tavakolinia, A Pourbagheri-Sigaroodi, A Safaroghli-Azar, ... International immunopharmacology 95, 107586, 2021 | 56 | 2021 |
| Platelets in the perspective of COVID-19; pathophysiology of thrombocytopenia and its implication as prognostic and therapeutic opportunity M Delshad, A Safaroghli-Azar, A Pourbagheri-Sigaroodi, B Poopak, ... International immunopharmacology 99, 107995, 2021 | 53 | 2021 |
| Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid) B Kashani, Z Zandi, D Bashash, A Zaghal, M Momeny, EM Poursani, ... Cancer Chemotherapy and Pharmacology 85, 47-59, 2020 | 49 | 2020 |
| The PI3K/Akt/mTOR axis in colorectal cancer: oncogenic alterations, non‐coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles MJ Sanaei, A Baghery Saghchy Khorasani, A Pourbagheri‐Sigaroodi, ... Journal of Cellular Physiology 237 (3), 1720-1752, 2022 | 48 | 2022 |
| Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities D Bashash, Z Zandi, B Kashani, A Pourbagheri‐Sigaroodi, S Salari, ... Journal of cellular physiology 237 (1), 346-372, 2022 | 32 | 2022 |
| Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities S Moradinasab, A Pourbagheri-Sigaroodi, P Zafari, SH Ghaffari, ... International Immunopharmacology 97, 107694, 2021 | 30 | 2021 |
| The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities MJ Sanaei, A Pourbagheri-Sigaroodi, V Kaveh, SA Sheikholeslami, ... Critical Reviews in Oncology/Hematology 157, 103160, 2021 | 30 | 2021 |
| The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle E Masoumi, S Tahaghoghi-Hajghorbani, L Jafarzadeh, MJ Sanaei, ... Journal of Controlled Release 340, 168-187, 2021 | 29 | 2021 |
| Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy MJ Sanaei, A Pourbagheri-Sigaroodi, V Kaveh, H Abolghasemi, ... European Journal of Pharmacology 909, 174404, 2021 | 29 | 2021 |
| The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with … N Akbari Dilmaghani, A Safaroghli‐Azar, A Pourbagheri‐Sigaroodi, ... IUBMB life 73 (4), 618-642, 2021 | 28 | 2021 |
| Phosphoinositide 3-kinase (PI3K) classes: From cell signaling to endocytic recycling and autophagy A Safaroghli-Azar, MJ Sanaei, A Pourbagheri-Sigaroodi, D Bashash European Journal of Pharmacology 953, 175827, 2023 | 27 | 2023 |
| Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance Z Zandi, B Kashani, Z Alishahi, A Pourbagheri-Sigaroodi, F Esmaeili, ... Journal of Cancer Research and Clinical Oncology 148 (1), 57-70, 2022 | 27 | 2022 |
